Photo by Nguyễn Hiệpi on Unsplash

WHO advises against convalescent plasma treatment for COVID-19

Embargoed until: Publicly released:
Peer-reviewed: This work was reviewed and scrutinised by relevant independent experts.

Meta-analysis: This type of study involves using statistics to combine the data from multiple previous studies to give an overall result. The reliability of a meta-analysis depends on both the quality and similarity of the individual studies being grouped together.

Randomised controlled trial: Subjects are randomly assigned to a test group, which receives the treatment, or a control group, which commonly receives a placebo. In 'blind' trials, participants do not know which group they are in; in ‘double blind’ trials, the experimenters do not know either. Blinding trials helps removes bias.

People: This is a study based on research using people.

Blood transfusions from people who have recovered from COVID-19 are ineffective, expensive, and time-consuming, according to updated guidelines from the World Health Organisation. Following expert analysis of 16 trials involving more than 16,000 patients, the WHO Guideline Development Group has confirmed that there is no clear evidence that the treatment reduces mortality nor the need for ventilators in patients with non-severe, severe, or critical COVID-19.

Journal/conference: The BMJ

Link to research (DOI): 10.1136/bmj.m3379

Organisation/s: World Health Organization (WHO)

Funder: N/A

Media release

From: The BMJ

WHO advises against use of convalescent plasma for covid-19

Current evidence shows no improvement in survival and other important measures

Convalescent plasma (a transfusion of blood plasma from someone who has recovered from covid-19) is not recommended for patients with covid-19, says a WHO Guideline Development Group of international experts in The BMJ today.

Despite its initial promise, current evidence shows that it does not improve survival nor reduce the need for mechanical ventilation, and it is costly and time-consuming to administer.

As such, the WHO makes a strong recommendation against the use of convalescent plasma in patients with non-severe illness, and a recommendation against its use in patients with severe and critical illness, except in the context of a randomised controlled trial (RCT).

The recommendations are based on evidence from 16 trials involving 16,236 patients with non-severe, severe, and critical covid-19 infection.

They are part of a living guideline, developed by the World Health Organization with the methodological support of MAGIC Evidence Ecosystem Foundation, to provide trustworthy guidance on the management of covid-19 and help doctors make better decisions with their patients.

Living guidelines are useful in fast moving research areas like covid-19 because they allow researchers to update previously vetted and peer reviewed evidence summaries as new information becomes available.

To make their recommendations, the panel considered a combination of evidence assessing relative benefits and harms, values and preferences, and feasibility issues.

The strong recommendation for patients with non-severe illness reflects the panel’s view that drug treatment in patients with a low risk of mortality and other important clinical outcomes is not justified.

And although convalescent plasma should not be used routinely in any patients, regardless of how severely ill they are, the panel acknowledged that there was sufficient uncertainty in patients with severe and critical illness to warrant continuation of RCTs.

They also noted several practical challenges, such as the need to identify and test potential donors, as well as collect, store and administer donor plasma, which they say further limits its feasibility and applicability.

After thoroughly reviewing all the information, the panel judged that almost all well informed patients would choose not to receive convalescent plasma.

Today’s guidance adds to previous recommendations for the use of interleukin-6 receptor blockers and systemic corticosteroids for patients with severe or critical covid-19; conditional recommendations for the use of neutralising monoclonal antibodies in selected patients and against the use of ivermectin and hydroxychloroquine in patients with covid-19 regardless of disease severity.

Attachments:

Note: Not all attachments are visible to the general public

News for:

International

Media contact details for this story are only visible to registered journalists.